ATE523488T1 - Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung - Google Patents

Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung

Info

Publication number
ATE523488T1
ATE523488T1 AT06774260T AT06774260T ATE523488T1 AT E523488 T1 ATE523488 T1 AT E523488T1 AT 06774260 T AT06774260 T AT 06774260T AT 06774260 T AT06774260 T AT 06774260T AT E523488 T1 ATE523488 T1 AT E523488T1
Authority
AT
Austria
Prior art keywords
histamine
preparation
therapeutic use
compounds
receptor agents
Prior art date
Application number
AT06774260T
Other languages
English (en)
Inventor
Lisa Beavers
Don Finley
Robert Gadski
Philip Hipskind
William Hornback
Cynthia Jesudason
Richard Pickard
Takako Takakuwa
Grant Vaught
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE523488T1 publication Critical patent/ATE523488T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
AT06774260T 2005-07-01 2006-06-28 Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung ATE523488T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69625705P 2005-07-01 2005-07-01
PCT/US2006/025328 WO2007005503A1 (en) 2005-07-01 2006-06-28 Histamine h3 receptor agents, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
ATE523488T1 true ATE523488T1 (de) 2011-09-15

Family

ID=37131500

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06774260T ATE523488T1 (de) 2005-07-01 2006-06-28 Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung

Country Status (11)

Country Link
US (1) US8008296B2 (de)
EP (2) EP2322506A1 (de)
JP (1) JP5193033B2 (de)
CN (1) CN101263112B (de)
AT (1) ATE523488T1 (de)
AU (1) AU2006265997B2 (de)
BR (1) BRPI0613495A2 (de)
CA (1) CA2613192C (de)
ES (1) ES2370518T3 (de)
MX (1) MX2007016216A (de)
WO (1) WO2007005503A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008301B2 (en) 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
NZ584688A (en) * 2007-10-17 2011-12-22 Sanofi Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
KR20100082349A (ko) 2007-10-17 2010-07-16 사노피-아벤티스 치환된 ｎ－페닐-비피롤리딘 우레아 및 이의 치료적 용도
RU2477720C2 (ru) * 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их применение в лечебных целях
KR20100092443A (ko) * 2007-10-17 2010-08-20 사노피-아벤티스 치환된 ｎ-페닐-피롤리디닐메틸피롤리딘 아미드 및 히스타민 ｈ3 수용체 조절제로서의 이의 치료적 용도
AR074467A1 (es) * 2008-12-05 2011-01-19 Sanofi Aventis Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
AU2002254114A1 (en) * 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
CN1625554A (zh) 2002-02-01 2005-06-08 诺沃挪第克公司 氨基烷基－取代的氮杂环丁烷、吡咯烷、哌啶与氮杂环庚烷的酰胺
WO2004037257A1 (en) * 2002-10-23 2004-05-06 Janssen Pharmaceutica, N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
PL376301A1 (en) 2002-10-24 2005-12-27 Sterix Limited Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
US7632857B2 (en) * 2004-04-01 2009-12-15 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
JP4572566B2 (ja) * 2004-04-09 2010-11-04 マックス株式会社 自走式ステープラ
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists

Also Published As

Publication number Publication date
CN101263112B (zh) 2012-10-10
CA2613192C (en) 2013-12-31
AU2006265997A1 (en) 2007-01-11
US20100160319A1 (en) 2010-06-24
WO2007005503A1 (en) 2007-01-11
MX2007016216A (es) 2008-03-11
EP1904442A1 (de) 2008-04-02
EP2322506A1 (de) 2011-05-18
JP5193033B2 (ja) 2013-05-08
BRPI0613495A2 (pt) 2011-01-11
AU2006265997B2 (en) 2011-11-17
US8008296B2 (en) 2011-08-30
ES2370518T3 (es) 2011-12-19
CN101263112A (zh) 2008-09-10
JP2009500335A (ja) 2009-01-08
EP1904442B1 (de) 2011-09-07
CA2613192A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
ATE455756T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
DE602005018758D1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
CY1110453T1 (el) Αναστολεις υποδοχεα η3 ισταμινης, παρασκευη και θεραπευτικες χρησεις

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties